{"id":"ketamine-venlafaxine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Increased heart rate"},{"rate":"5-10%","effect":"Increased blood pressure"}]},"_chembl":{"chemblId":"CHEMBL742","moleculeType":"Small molecule","molecularWeight":"237.73"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ketamine's mechanism of action involves blocking the NMDA receptor, which is involved in the regulation of synaptic plasticity and memory formation. Venlafaxine, on the other hand, works by inhibiting the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft and enhancing neurotransmission.","oneSentence":"Ketamine is an NMDA receptor antagonist, while venlafaxine is a serotonin-norepinephrine reuptake inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:44.694Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"},{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT07230171","phase":"NA","title":"The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-09-15","conditions":"Fibromyalgia, Pregabalin, Esketamine","enrollment":106},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT06508710","phase":"PHASE3","title":"Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-10-20","conditions":"Major Depressive Episode","enrollment":60},{"nctId":"NCT02417064","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-10","conditions":"Treatment-resistant Depression","enrollment":346},{"nctId":"NCT03434041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-25","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":252},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02418585","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-07","conditions":"Treatment-resistant Depression","enrollment":236},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT01557712","phase":"PHASE3","title":"Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2012-03","conditions":"Major Depressive Disorder","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":65,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ketamine venlafaxine","genericName":"ketamine venlafaxine","companyName":"University Hospital, Grenoble","companyId":"university-hospital-grenoble","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ketamine is an NMDA receptor antagonist, while venlafaxine is a serotonin-norepinephrine reuptake inhibitor. Used for Treatment-resistant depression, Major depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}